Drug halves alcohol consumption to aid alcohol dependence
Drug Discovery World
NOVEMBER 8, 2023
Kinnov Therapeutics’ Phase II study for its lead compound KT-110 has shown that the treatment can halve alcohol consumption amongst heavy drinkers in three months. The trial showed that KT-110 has superior efficacy in significantly reducing alcohol consumption in heavy drinkers by 26 to 30 grams (2.6-3 drinks) per day compared to the placebo. This increased to 50 grams (five drinks) per day compared to the baseline measure at the start of treatment.
Let's personalize your content